Skip to main content

Table 2 UPDRS scores and NMSS scores at baseline and end of treatment

From: Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease

 

Baseline (n = 114)

End of Treatment (n = 112)

Difference (n = 112)

UPDRS

   

   I

1.9 ± 1.8

1.4 ± 1.6

-0.5 ± 1.2

   II

7.8 ± 5.3

6.9 ± 4.9

-0.9 ± 3.3

   III

17.9 ± 10.3

15.9 ± 10.0

-1.9 ± 5.9

   IV

2.7 ± 3.1

2.2 ± 2.8

-0.4 ± 1.8

 

Baseline (n = 114)

End of Treatment (n = 111)

Difference (n = 111)

NMSS

   

   Total

29.5 ± 30.5

21.8 ± 22.2

-7.9 ± 19.8

   Cardiovascular

0.8 ± 1.3

0.7 ± 2.6

-0.0 ± 2.7

   Sleep/fatigue

5.8 ± 7.3

4.8 ± 6.0

-0.9 ± 6.7

   Mood/cognition

4.6 ± 9.1

2.7 ± 6.6

-1.9 ± 6.2

   Perceptual problems

0.2 ± 1.3

0.1 ± 0.7

-0.1 ± 1.1

   Attention/memory

3.4 ± 4.7

2.4 ± 4.1

-1.0 ± 3.7

   Gastrointestinal

2.3 ± 4.0

1.7 ± 3.0

-0.6 ± 3.6

   Urinary

6.3 ± 9.9

5.2 ± 7.6

-1.3 ± 5.3

   Sexual dysfunction

1.3 ± 3.5

0.9 ± 3.2

-0.4 ± 1.8

   Miscellaneous

4.8 ± 6.4

3.3 ± 5.4

-1.6 ± 5.6

  1. UPDRS, Unified Parkinson's Disease Rating Scale; NMSS, Non-Motor Symptom Scale.
  2. Plus-minus values are mean ± SD (Standard Deviation).